MediRama Shares Latest Insights on Cancer Treatment Through 'ASCO 2024 Highlights'

Medirama announced on the 2nd that it held 'Medirama Highlights ASCO 2024,' a networking event for stakeholders in the field of anticancer new drugs to share major research results introduced at the American Society of Clinical Oncology (ASCO) last month on the 27th and their opinions.

On the 27th of last month, 'Medirama Highlights ASCO 2024' was held at the Yuhan Corporation building in Dongjak-gu, Seoul.
[Photo by Medirama]

This year's ASCO, held from May 31 to June 4 (local time) in Chicago, USA, was attended by about 40,000 clinicians, scientists, patient organizations, and industry stakeholders under the theme of 'The Art and Science of Cancer Treatment.' At this conference, a total of 250 oral presentations and over 2,500 poster presentations were conducted across 24 sessions.

This event was organized for those who could not attend the event in person due to distance and time constraints or found it difficult to fully grasp all the major contents due to the physically vast disclosure of research results. The event, held at the 15th-floor conference room of Yuhan Corporation located in Dongjak-gu, Seoul, was attended by about 100 representatives from pharmaceutical companies, biotech firms, investors, and media.

Presentations were given by Kim Jeong-ah, Director of the Hematologic Cancer Center at St. Vincent's Hospital, Catholic University Medical School, as well as Medirama's CEO Moon Han-lim, Executive Director Oh Bit-na, and Director Kim In-young. Through these presentations, notable research on ▲immuno-oncology drugs ▲targeted therapies ▲novel biomarkers was introduced.

Seo Soo-kyung, Vice President of Medirama, said, "More than 20 biotech companies from Korea participated in ASCO 2024 this year, showing the highest participation rate to date, and among them, some companies presented Phase 3 clinical trial results. As Korean pharmaceutical companies have grown enough to make their names known in the global market, we expect biotech companies, which are currently going through a difficult period due to recent investment sentiment contraction, to use this year as a turning point for greater growth."